The BioIndustry Association (BIA) and the Ethical Medicines Industry Group (EMIG) are joining forces again to co-host a one-day event in central London on 1 May, which will bring together senior policy makers and experts from across the bioscience and pharmaceutical sectors to discuss the impact of the government’s reforms of the National Health Service (NHS).
The conference will examine the key issues of the reforms, including: the role of Clinical Commissioning Groups (CCGs) in the new commissioning landscape; the Quality, Innovation, Productivity and Prevention (QIPP) agenda; market access issues including reforms to NICE and new approaches to pricing; and the Cancer Drugs Fund.
“The NHS reforms and transition process remains one of the major opportunities – and yet the biggest threat – to both BIA’s and EMIG’s membership,” said Glyn Edwards, Interim Chief Executive of the BIA.
“This joint event will explore how the both bioscience and pharma companies should respond to this, focusing particularly on the new commissioning pathways, the changing role of NICE and the ongoing delivery of the QIPP agenda.
“We are delighted to be working in partnership with EMIG once again in order to continue to foster new business development opportunities across our memberships by facilitating senior level networking.
“This further reflects the BIA’s ongoing commitment to collaborate with other organisations to foster more partnership working across the life sciences sector.”
Leslie Galloway, Chairman of EMIG, said: “EMIG and BIA have, once again, worked closely to design an event that will enable members of both organisations and those from the health and life sciences sector to focus on the challenges and opportunities resulting from the significant changes to our healthcare system.
“The government’s reforms will create a significant upheaval in how the climate for research within the NHS will change and this event will be vital in enabling EMIG and BIA members to understand and shape the future system.”